摘要
Hepatitis C virus （HCV） is an important human liver pathogen that has infected over 170 million people worldwide, often leading to liver cirrhosis and hepatocellular carcinoma [1]. While the efficacies of novel inhibitors of the viral polymerase and protease enzymes are being explored in numerous clinical trials, current therapies against HCV infections are limited to a combined administration ofpegylated interferon-or and ribavirin. However, this combination therapy has considerable side effects, which include influenza-like symptoms, depression and anemia [2].
